Skip to main content

Jaume Alijotas Reig

Institutions of which they are part

Head of group
Systemic Diseases
Vall Hebron Institut de Recerca

Jaume Alijotas Reig

Institutions of which they are part

Head of group
Systemic Diseases
Vall Hebron Institut de Recerca

Research lines

Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses.

Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments.

IP: Jaume Alijotas Reig

Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia.

Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic).

IP: Jaume Alijotas Reig

Pathogenic role of cellular microparticles and anti-phospholipid/anti-cofactor antibodies in recurrent implantation failures related to In Vitro Fertilization (IVF).

The prevalence of failed IVF is high or very high. Besides problems intrinsic to the technique, we know almost nothing about the possible underlying causes. Anti-phospholipid/anti-cofactor (aPL/aCF) antibodies have been associated to several obstetric complications. Nevertheless, the role that these aPL/aCF antibodies may have in failed IVF is not well defined. With this randomized study we want to understand better the use that these antibodies may have on a clinical daily basis. Along with the microparticles analysis, we could end up by finding several elements that might act as risk markers; in turn, it might even help us to fine-tune the currently used therapeutic approaches.

IP: Jaume Alijotas Reig

Development of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS/EUROMAP).

The so-called obstetric antiphospholipid syndrome seems to have pathogenic, biologic, therapeutic, and evolution features somehow different from the ones observed in those patients who suffer from "classic" antiphospholipid syndrome. Although experience and scientific evidence seem to support this idea, there is a lack of information that allows us to suggest changes in the classification and/or therapeutic criteria. The European Forum on Antiphospholipid Antibody Syndrome has decided to carry on this project and it has chosen the Vall d'Hebron Hospital as the European Coordinating Centre. Many important Spanish and European hospitals will participate in this multicentric study.

IP: Jaume Alijotas Reig

Projects

Anticuerpos antifosfolipídicos inductores de memoria inmune innata en monocitos como causa de morbilidad obstétrica en el síndrome antifosfolipídico.

IP: Francesc Miro Mur
Collaborators: Jaume Alijotas Reig, Anticuerpos antifosfolipídicos inductores de memoria inmune innata en monocitos como causa de morbilidad obstétrica en el síndr, José Pardos Gea, Anticuerpos antifosfolipídicos inductores de memoria inmune innata en monocitos como causa de morbilidad obstétrica en el síndr, Ariadna Anunciacion Llunell, Joana Rita Marques Soares
Funding agency: Instituto de Salud Carlos III
Funding: 102500
Reference: PI24/01302
Duration: 01/01/2025 - 31/12/2027

Ajuts Grups de Recerca (SGR) 2022

IP: Jaume Alijotas Reig
Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Ajuts Grups de Recerca (SGR) 2022, Ariadna Anunciacion Llunell
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00048
Duration: 01/01/2022 - 30/06/2025

Be Sure genetic test to determine dermal filler implant adverse reactions

IP: Jaume Alijotas Reig
Collaborators: -
Funding agency: CERCA (Centres de Recerca de Catalunya)
Funding: 10000
Reference: 2020-07-010
Duration: 01/01/2019 - 31/12/2020

Factores angiogénicos durante la gestación y riesgo cardiovascular a medio-largo plazo en las pacientes con preeclampsia. Abordaje clínico y experimental.

IP: Jaume Alijotas Reig
Collaborators: Manel Mendoza Cobaleda, Josep Perapoch López
Funding agency: Instituto de Salud Carlos III
Funding: 71995
Reference: PI16/01997
Duration: 01/01/2017 - 31/12/2019

Related news

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

Related professionals

JAUME VIMA BOFARULL

JAUME VIMA BOFARULL

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Monder Abu-Suboh Abadia

Monder Abu-Suboh Abadia

Physiology and Pathophysiology of the Digestive Tract
Read more
David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
Carole Conforti

Carole Conforti

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.